Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Head and Neck Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Sarcoma 1Lymphoma 1Lymphedema 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Fibrosis 1Deglutition Disorders 1Congenital Abnormalities 1

Interventions

Bevacizumab 69Sorafenib 66lenvatinib 59durvalumab 38sintilimab 33Nivolumab 32tislelizumab 28atezolizumab 28pembrolizumab 27Oxaliplatin 26tremelimumab 23apatinib 22Fluorouracil 22Radiosurgery 20regorafenib 19camrelizumab 18Doxorubicin 18cabozantinib 16Leucovorin 16Capecitabine 16Radiotherapy 14Folfox protocol 14donafenib 13Gemcitabine 13Cisplatin 12toripalimab 11Erlotinib Hydrochloride 10spartalizumab 8anlotinib 8Neoadjuvant Therapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Hepatocellular × Pravastatin × Clear all
NCT03219372 2021-01-22

Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence

Cedars-Sinai Medical Center

Phase 2 Terminated
1 enrolled 5 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT01357486 2017-05-01

PRODIGE 21

University Hospital, Bordeaux

Phase 2 Completed
160 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡